04/27/2025

Report Finds Pharma Tariffs Would Inflate U.S. Drug Costs by $51 Billion Annually

If fully passed on to Americans, the tariffs would boost US drug prices by 12.9 percent

A 25 percent U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9 percent if passed on, a report commissioned by the industry's U.S. trade group and reviewed by Reuters shows.

The analysis, conducted by Ernst & Young, found the United States imported $203 billion in pharmaceutical products in 2023, with 73 percent coming from Europe, primarily Ireland, Germany and Switzerland. Total U.S. sales of finished pharmaceuticals that year were $393 billion.

The report, dated April 22 and not made public, was commissioned by the main U.S. pharmaceutical lobby, the Pharmaceutical Research and Manufacturers of America, whose members include Amgen, Bristol Myers Squibb, Eli Lilly and Pfizer, among others.

Please select this link to read the complete article from Reuters.